BTS Multidrug-resistant Tuberculosis Clinical Advice Service Database
Research type
Research Database
IRAS ID
214602
Contact name
Onn Min Kon
Contact email
Research summary
British Thoracic Society Multidrug-resistant Tuberculosis Clinical Advice Service Database
REC name
London - South East Research Ethics Committee
REC reference
17/LO/1539
Date of REC Opinion
27 Oct 2017
REC opinion
Favourable Opinion
Data collection arrangements
Subjects will be individuals with MDR-TB (or other complex TB/mycobacterium infections) in the UK. Data collected will be demographic data together with clinical data relating to the patient’s infection, treatment and outcomes (including drug sensitivities, culture results, x-rays, etc.). Information on other drugs the patient would be taking which may negatively interact with the patient’s treatment (such as named HIV drugs) would also be collected. Ongoing information on disease status and treatment history would also be entered onto the database. The data collection templated are included with this application, for information.
Data collection will be undertaken by clinical personnel (doctors or nurses) at participating centres. Information on drug sensitivities and patient demographics will be uploaded directly from Public Health England (PHE) to ensure the panel of MDR-TB expert advisers will have access to accurate information at the earliest possible opportunity.
Research programme
The database will provide an easily accessed system for data collection regarding cases of MDR-TB and other complex TB/mycobacterial infections in the UK. This data collection serves two purposes: 1) MDR-TB is rare in the UK and can be extremely difficult to treat. Many clinicians are not experienced with treating patients with MDR-TB, therefore advice on patient treatment from MDR-TB experts would be invaluable. The BTS MDR-TB database enables the provision of consensus advice on patient treatment from an appointed group of MDR-TB experts. Additionally, advice on treatment can be provided to clinicians throughout the time the patient is treated – this includes ongoing advice in the event of adverse drug reactions, etc. 2) The provision of a nationwide database for patients with MDR-TB allows the analysis of data regarding patient response to treatment, including adverse reactions and long term outcomes. Analysis of the database would allow for a greater understanding of UK drug toxicity patterns. Additionally, analysis of the data will support the development of research programmes in the UK respiratory research community under the aegis of the British Thoracic Society.
Research database title
British Thoracic Society Multidrug-resistant Tuberculosis Clinical Advice Service Database
Establishment organisation
British Thoracic Society
Establishment organisation address
17 Doughty Street
London
WC1N 2PL